A detailed history of Mirador Capital Partners LP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Mirador Capital Partners LP holds 11,997 shares of GILD stock, worth $800,079. This represents 0.17% of its overall portfolio holdings.

Number of Shares
11,997
Previous 11,144 7.65%
Holding current value
$800,079
Previous $902,000 2.66%
% of portfolio
0.17%
Previous 0.19%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$71.58 - $87.29 $61,057 - $74,458
853 Added 7.65%
11,997 $878,000
Q4 2023

Jan 19, 2024

BUY
$73.27 - $83.09 $54,512 - $61,818
744 Added 7.15%
11,144 $902,000
Q3 2023

Oct 05, 2023

BUY
$73.94 - $80.67 $52,571 - $57,356
711 Added 7.34%
10,400 $779,000
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $2,052 - $2,340
-27 Reduced 0.28%
9,689 $746,000
Q1 2023

Apr 14, 2023

SELL
$77.31 - $88.08 $384,308 - $437,845
-4,971 Reduced 33.85%
9,716 $806,000
Q4 2022

Feb 09, 2023

BUY
$62.32 - $89.47 $4,674 - $6,710
75 Added 0.51%
14,687 $1.26 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $8,871 - $10,133
-149 Reduced 1.01%
14,612 $901,000
Q2 2022

Aug 05, 2022

BUY
$57.72 - $65.01 $36,017 - $40,566
624 Added 4.41%
14,761 $912,000
Q1 2022

May 06, 2022

BUY
$57.92 - $72.58 $108,136 - $135,506
1,867 Added 15.22%
14,137 $840,000
Q4 2021

Feb 02, 2022

BUY
$64.88 - $73.64 $14,727 - $16,716
227 Added 1.88%
12,270 $891,000
Q3 2021

Nov 09, 2021

SELL
$67.69 - $73.03 $1,083 - $1,168
-16 Reduced 0.13%
12,043 $841,000
Q2 2021

Jul 27, 2021

SELL
$63.47 - $69.35 $1.59 Million - $1.73 Million
-24,992 Reduced 67.45%
12,059 $830,000
Q1 2021

Apr 29, 2021

BUY
$60.0 - $68.46 $83,280 - $95,022
1,388 Added 3.89%
37,051 $2.4 Million
Q4 2020

Jan 20, 2021

BUY
$56.65 - $64.55 $281,777 - $321,071
4,974 Added 16.21%
35,663 $2.08 Million
Q3 2020

Nov 12, 2020

BUY
$62.1 - $78.08 $22,107 - $27,796
356 Added 1.17%
30,689 $1.94 Million
Q2 2020

Aug 06, 2020

BUY
$72.34 - $84.0 $36,314 - $42,168
502 Added 1.68%
30,333 $2.33 Million
Q1 2020

May 11, 2020

BUY
$62.63 - $80.22 $506,363 - $648,578
8,085 Added 37.18%
29,831 $2.31 Million
Q4 2019

Jan 17, 2020

BUY
$61.62 - $67.78 $743,753 - $818,104
12,070 Added 124.74%
21,746 $1.41 Million
Q3 2019

Oct 31, 2019

BUY
$62.51 - $69.0 $8,938 - $9,867
143 Added 1.5%
9,676 $613,000
Q2 2019

Aug 06, 2019

SELL
$61.87 - $69.38 $5,877 - $6,591
-95 Reduced 0.99%
9,533 $644,000
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $233,737 - $261,846
3,738 Added 63.46%
9,628 $626,000
Q4 2018

Feb 13, 2019

SELL
$60.54 - $79.0 $10,776 - $14,062
-178 Reduced 2.93%
5,890 $368,000
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $71 - $78
1 Added 0.02%
6,068 $469,000
Q2 2018

Aug 08, 2018

SELL
$64.88 - $75.68 $320,701 - $374,086
-4,943 Reduced 44.9%
6,067 $430,000
Q1 2018

May 02, 2018

BUY
$72.84 - $88.8 $12,455 - $15,184
171 Added 1.58%
11,010 $795,000
Q4 2017

Feb 12, 2018

BUY
$71.15 - $83.52 $354,611 - $416,263
4,984 Added 85.12%
10,839 $777,000
Q3 2017

Nov 13, 2017

SELL
$72.11 - $85.47 $4,326 - $5,128
-60 Reduced 1.01%
5,855 $489,000
Q2 2017

Aug 08, 2017

BUY
N/A
5,915
5,915 $433,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.6B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Mirador Capital Partners LP Portfolio

Follow Mirador Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirador Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Mirador Capital Partners LP with notifications on news.